Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia

Leukemia(2024)10.1038/s41375-024-02493-3Source: DataRank Database

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia is a research paper published in Leukemia (2024). On theSindex it has a DataRank of 0.269. It has been cited 5 times.

N/A

0.269DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 0.90)OA: hybridTopics (74)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (12)

Lisa M Niswander ORCID,Asen Bagashev ORCID,Joseph P. Loftus,Savannah Ross,Robert Chen ORCID

Live enrichment

PubMed:39681640 PMC:PMC11879877 OpenAlex:https://openalex.org/W4405429159

NICHD NIH HHS

Grant: K12 HD043245

U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)

Grant: U01CA232486

U.S. Department of Defense (United States Department of Defense)

Grant: W81XWH-19-1-0196

NCI NIH HHS

Grant: T32 CA009615

NICHD NIH HHS

Grant: T32 HD043021

NCI NIH HHS

Grant: U01 CA243072

U.S. Department of Defense (United States Department of Defense)

Grant: W81XWH-19-1-0197

National Institutes of Health

Grant: 5T32CA009615-24

Cancer Center Research Training Program

National Institutes of Health

Grant: 5K12HD043245-08

CHOP Pediatrics Scholars Program

National Institutes of Health

Grant: 5U01CA243072-05

Towards rational design of combination therapeutic targets

National Institutes of Health

Grant: 1U01CA232486-01

Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissions

National Institutes of Health

Grant: 1T32HD043021-01

CHOP Institutional Training in Pediatric Research

FWCI

0.90

Citation Percentile

0.8%

Citation Trend

2025

hybridLicense: cc-by

journalhttps://www.nature.com/articles/s41375-024-02493-3.pdf

publisherhttps://www.nature.com/articles/s41375-024-02493-3.pdf

publisherhttps://www.nature.com/articles/s41375-024-02493-3

journalhttps://doi.org/10.1038/s41375-024-02493-3

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39681640

Fields of Study

CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchImmune Cell Function and Interaction0301 basic medicine0303 health sciences03 medical and health sciencesHumansAnimalsReceptors, CytokineMicePrecursor Cell Lymphoblastic Leukemia-LymphomaPyrimidinesDown SyndromePyrazolesPhiladelphia ChromosomeGene RearrangementXenograft Model Antitumor AssaysNitrilesDrug Resistance, NeoplasmImmunotherapyCell Proliferation

MeSH Terms

AnimalsDown SyndromeHumansImmunotherapyNitrilesPhiladelphia ChromosomePyrazolesPyrimidinesGene RearrangementCytokinesReceptors, CytokineDrug Resistance, NeoplasmXenograft Model Antitumor AssaysCell Line, TumorCell ProliferationMicePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

RuxolitinibThymic stromal lymphopoietinMedicineCancer researchCytokineLeukemiaCytokine release syndromeCD19ImmunotherapyImmunologyAcute lymphocytic leukemiaIn vivoChimeric antigen receptorBlinatumomabAntigenPharmacologyBiologyBone marrowMyelofibrosisLymphoblastic LeukemiaImmune systemGene RearrangementPrecursor Cell Lymphoblastic Leukemia-LymphomaXenograft Model Antitumor AssaysArticleMicePyrimidinesDrug Resistance, NeoplasmNitrilesHumansAnimalsPyrazolesPhiladelphia ChromosomeReceptors, CytokineDown SyndromeCell Proliferation

Sustainable Development Goals

SDG 0: Good health and well-being

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia

FAIR Checklist

DataRank Breakdown

Authors (12)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)